Aims: Aging is associated with cognitive deterioration, and genetic factors are implicated in individual cognitive differences in the aged. The C677T mutation in the 5,10-methylenetetrahydrofolate reductase gene (MTHFR) yields a common thermolabile variant (T) with reduced enzyme activity and consequent elevation of serum homocysteine concentrations. We designed the present study to investigate whether this functional polymorphism may affect global and specific cognitive functions in older Chinese males without dementia. Methods: The subjects included 356 elderly males without major psychiatric disorders or dementia, who were assessed by the Cognitive Abilities Screening Instruments (CASI) and the Wechsler Digit Span Task tests. Results: A significant association was found between the MTHFR C677T polymorphism and total CASI scores (p = 0.012), particularly in short-term memory (p = 0.002) and concentration/mental manipulation (p = 0.007). Post hoc tests indicated that the C/T heterozygotes achieved better cognitive function test results than C/C or T/T carriers. No association was found between the MTHFR genotype and the Wechsler Digit Span Task tests. Conclusion: These results suggest that a heterozygote advantage exists for the MTHFR C677T polymorphism in specific cognitive functions in elderly Chinese males without dementia.

Keywords:
Aged, Cognitive function, Methylenetetrahydrofolate reductase, Polymorphism
1.
McClearn GE, Johansson B, Berg S, Pedersen NL, Ahern F, Petrill SA, Plomin R: Substantial genetic influence on cognitive abilities in twins 80 or more years old. Science 1997;276:1560–1563.
2.
Budge M, Johnston C, Hogervorst E, de Jager C, Milwain E, Iversen SD, Barnetson L, King E, Smith AD: Plasma total homocysteine and cognitive performance in a volunteer elderly population. Ann NY Acad Sci 2000;903:407–410.
3.
Duthie SJ, Whalley LJ, Collins AR, Leaper S, Berger K, Deary IJ: Homocysteine, B vitamin status, and cognitive function in the elderly. Am J Clin Nutr 2002;75:908–913.
4.
Kalmijn S, Launer LJ, Lindemans J, Bots ML, Hofman A, Breteler MM: Total homocysteine and cognitive decline in a community-based sample of elderly subjects: the Rotterdam Study. Am J Epidemiol 1999;150:283–289.
5.
Teunissen CE, van Boxtel MP, Jolles J, de Vente J, Vreeling F, Verhey F, Polman CH, Dijkstra CD, Blom HJ: Homocysteine in relation to cognitive performance in pathological and non-pathological conditions. Clin Chem Lab Med 2005;43:1089–1095.
6.
Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, Selhub J, Rozen R: Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996;93:7–9.
7.
Gussekloo J, Heijmans BT, Slagboom PE, Lagaay AM, Knook DL, Westendorp RG: Thermolabile methylenetetrahydrofolate reductase gene and the risk of cognitive impairment in those over 85. J Neurol Neurosurg Psychiatry 1999;67:535–538.
8.
Almeida OP, Flicker L, Lautenschlager NT, Leedman P, Vasikaran S, van Bockxmeer FM: Contribution of the MTHFR gene to the causal pathway for depression, anxiety and cognitive impairment in later life. Neurobiol Aging 2005;26:251–257.
9.
Bathum L, von Bornemann Hjelmborg J, Christiansen L, McGue M, Jeune B, Christensen K: Methylenetetrahydrofolate reductase 677C>T and methionine synthase 2756A>G mutations: no impact on survival, cognitive functioning, or cognitive decline in nonagenarians. J Gerontol A Biol Sci Med Sci 2007;62:196–201.
10.
de Lau LM, van Meurs JB, Uitterlinden AG, Smith AD, Refsum H, Johnston C, Breteler MM: Genetic variation in homocysteine metabolism, cognition, and white matter lesions. Neurobiol Aging 2010;31:2020–2022.
11.
Visscher PM, Tynan M, Whiteman MC, Pattie A, White I, Hayward C, Wright AF, Starr JM, Whalley LJ, Deary IJ: Lack of association between polymorphisms in angiotensin-converting-enzyme and methylenetetrahydrofolate reductase genes and normal cognitive ageing in humans. Neurosci Lett 2003;347:175–178.
12.
Schiepers OJ, van Boxtel MP, Harris SE, Gow AJ, Pattie A, Brett CE, de Groot RH, Jolles J, Starr JM, Deary IJ: MTHFR polymorphisms and cognitive ageing in the ninth decade: the Lothian Birth Cohort 1921. Genes Brain Behav 2011;10:354–364.
13.
Cheng DM, Jiang YG, Huang CY, Kong HY, Pang W, Yang HP: Polymorphism of MTHFR C677T, serum vitamin levels and cognition in subjects with hyperhomocysteinemia in China. Nutr Neurosci 2010;13:175–182.
14.
Elkins JS, Johnston SC, Ziv E, Kado D, Cauley JA, Yaffe K: Methylenetetrahydrofolate reductase C677T polymorphism and cognitive function in older women. Am J Epidemiol 2007;166:672–678.
15.
Durga J, van Boxtel MP, Schouten EG, Bots ML, Kok FJ, Verhoef P: Folate and the methylenetetrahydrofolate reductase 677C–>T mutation correlate with cognitive performance. Neurobiol Aging 2006;27:334–343.
16.
Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC: The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(suppl 20):22–33.
17.
Teng EL, Hasegawa K, Homma A, Imai Y, Larson E, Graves A, Sugimoto K, Yamaguchi T, Sasaki H, Chiu D: The Cognitive Abilities Screening Instrument (CASI): a practical test for cross-cultural epidemiological studies of dementia. Int Psychogeriatr 1994;6:45–58.
18.
Liu HC, Chou P, Lin KN, Wang SJ, Fuh JL, Lin HC, Liu CY, Wu GS, Larson EB, White LR: Assessing cognitive abilities and dementia in a predominantly illiterate population of older individuals in Kinmen. Psychol Med 1994;24:763–770.
19.
Ho CH: The influence of age, sex, vitamin B(12), folate levels and methylenetetrahydrofolate reductase C677T genetic mutations on plasma homocysteine in the Chinese population. Haematologica 2000;85:1051–1054.
20.
Ruiz JR, Castillo R, Labayen I, Moreno LA, Fuentes MG, Lamuño DG, Alvarez Granda JL, Lucia A, Ortega FB; AVENA Study Group: Individual and combined effects of ApoE and MTHFR 677C/T polymorphisms on cognitive performance in Spanish adolescents: the AVENA study. J Pediatr 2010;156:978–984.
21.
Gosso MF, de Geus EJ, Polderman TJ, Boomsma DI, Heutink P, Posthuma D: Catechol O-methyl transferase and dopamine D2 receptor gene polymorphisms: evidence of positive heterosis and gene-gene interaction on working memory functioning. Eur J Hum Genet 2008;16:1075–1082.
22.
Gaspar DA, Matioli SR, de Cássia Pavanello R, Araújo BC, Alonso N, Wyszynski D, Passos-Bueno MR: Maternal MTHFR interacts with the offspring’s BCL3 genotypes, but not with TGFA, in increasing risk to nonsyndromic cleft lip with or without cleft palate. Eur J Hum Genet 2004;12:521–526.
23.
Bagley PJ, Selhub J: A common mutation in the methylenetetrahydrofolate reductase gene is associated with an accumulation of formylated tetrahydrofolates in red blood cells. Proc Natl Acad Sci USA 1998;95:13217–13220.
24.
Krupenko SA, Oleinik NV: 10-Formyltetrahydrofolate dehydrogenase, one of the major folate enzymes, is down-regulated in tumor tissues and possesses suppressor effects on cancer cells. Cell Growth Differ 2002;13:227–236.
25.
Oleinik NV, Krupenko SA: Ectopic expression of 10-formyltetrahydrofolate dehydrogenase in A549 cells induces G1 cell cycle arrest and apoptosis. Mol Cancer Res 2003;1:577–588.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.